Author of the publication

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Regulation of secretory transport by protein kinase D-mediated phosphorylation of the ceramide transfer protein, , , , , and . Journal of Cell Biology, 178 (1): 15--22 (2007)Selective activation of tumor necrosis factor receptor 2 induces anti-inflammatory responses and alleviates experimental arthritis, , , , , , , , , and 1 other author(s). Arthritis & Rheumatology, (January 2018)Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface, , , , and . Cancer Immunology, Immunotherapy, 55 (12): 1590--1600 (2006)Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration, , , , , , , , , and 4 other author(s). Proceedings of the National Academy of Sciences, 113 (43): 12304--12309 (October 2016)Superior properties of Fc-comprising scTRAIL fusion proteins, , , , , , , and . Molecular Cancer Therapeutics, 16 (12): molcanther.0551.2017 (December 2017)A Novel Functional Polymorphism in the Transforming Growth Factor-β2 Gene Promoter and Tumor Progression in Breast Cancer, , , , , , , , and . Cancer Research, 66 (15): 7554--7561 (August 2006)Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like, , , , , and . Cancer Research, 69 (14): 5634--5638 (2009)Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib, , , , , , , , , and 2 other author(s). Hepatology, 57 (2): 625--636 (February 2013)Improving TNF as a cancer therapeutic: Tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects, , and . BioFactors, 35 (4): 364--372 (2009)TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice, , , , , , , , , and 5 other author(s). Cell Death & Disease, 11 (3): 212 (2020)